CLINICAL DATA

+20 years of clinical validation.
200 research collaborations. 100s of publications


Scientific evidence for clinical utility.

By continually expanding and strengthening our database of proven research, we have gained widespread trust in the precision, accuracy and quality of our MammaPrint® and BluePrint® test suite.

Evidence

Equivalence of NGS-based MammaPrint 70-gene signature risk of recurrence and BluePrint 80-gene signature of molecular subtyping tests to the centralized microarray tests

Publication: ESMO BREAST CANCER CONGRESS 2022AuthorsEsther Schuler(1), Sahra Uygun(2), Lorenza Mittempergher(3), Darina Pronin(3), Sammy Mee(2), Simon Bao(2), Tyson Cavness(2), Anke Witteveen(3), and Annuska Glas(3)1. Zotz|Klimas, MVZ Düsseldorf-Centrum GbR, Germany 2. Agendia Inc., Irvine, CA 3. Agendia NV., Amsterdam, NetherlandsBackgroundThe MammaPrint® 70-gene signature (70GS) risk of recurrence and BluePrint® 80-gene signature Read More

Molecular profiles of genomically High Risk ER+ HER2- breast cancer tumors classified as functionally Basal or Luminal B by the BluePrint

PUBLICATION: ASCO 2021 Authors Joyce O’Shaughnessy1, Virginia G. Kaklamani2, Yuan Yuan3, Julie Barone4, Sami Diab5, Jennifer A. Crozier6, Pat W. Whitworth7, Karen L. Tedesco8, Robert Maganini9, Rakhshanda Layeequr Rahman10, Carlos A. Encarnacion11, Josien Haan12, Amy M. Truitt12, Andrea Menicucci12, William Audeh12, FLEX Investigators’ Group13 Background The 80-gene signature (BluePrint/BP) Read More

Whole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients ≤ 50 years and > 50 years

PUBLICATION: ASCO 2021 Authors Cathy Graham1, Douglas K. Marks2, Nina D’Abreo2, Sami Diab3, Vijayakrishna K. Gadi4, Midas M. Kuilman5, Andrea Menicucci6, Amy M. Truitt6, Shiyu Wang6, Patricia Dauer6, William Audeh6, FLEX Investigators’ Group8 Background Recent prospective clinical trials have demonstrated a differential chemotherapy effect based on age (≤ 50 Read More

Gene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer

PUBLICATION: ASCO 2021 Authors Nina D’Abreo1,2, Abhinav Rohatgi1,2, Douglas Kanter Marks1,2, Heather M. Kling3, Josien Haan4, William Audeh3, FLEX Investigators Group5 Background Lymphovascular invasion (LVI), the passage of carcinoma cells through lymphatic and blood vessels, is an important early step in metastasis; however, LVI is excluded from most breast Read More

MammaPrint, BluePrint, and Full-genome Data Linked with Clinical Data to Evaluate New Gene EXpression Profiles (FLEX): A real-world dataset and investigator-initiated protocols in ESBC

  Publication: St. Gallen Authors: Jennifer A. Crozier, Lisa Blumencranz, Miranda Kleijn, Heather Kling, Amy M. Truitt, Darina Proni, Christine Finn, William Audeh, Bastiaan van der Baan, FLEX Investigators’ Group Background: The personalized management of early-stage breast cancers is enhanced by the ability of genomic signatures to stratify tumors into Read More

5-year distant metastasis-free survival outcomes on the pre-operative use of MammaPrint and BluePrint for neoadjuvant decisions in the NBREaST II trial

Publication: St. Gallen Authors: E. Göker, M.P. Hendriks, M. van Tilburg, A. Barcaru, L. Mittempergher, A. van Egmond, M. Kleijn and D. Generali Background: The 80-gene signature BluePrint® (BP) discriminates between three distinctive molecular subtypes: Luminal-type, HER2-type and Basal-type.1 Combined with the 70-gene signature MammaPrint® (MP), BP can further stratify Read More